SOLIGENIX, INC. Adjustments to Additional Paid in Capital, Other
SOLIGENIX, INC. (SNGX) reported Adjustments to Additional Paid in Capital, Other of -$192.13 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2019-11-12
- SOLIGENIX, INC. adjustments to additional paid in capital, other for the quarter ending 2018-09-30 was -$192.13K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 9 month |
|---|---|---|
| 2018-09-30 | -$192.13K 10-Q · filed 2019-11-12 | -$192.13K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |